NCT05692934View on ClinicalTrials.gov

A HR20031 FE Study on Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

March 11, 2023

Study Completion Date

March 11, 2023

Conditions
Type 2 Diabetes
Interventions
DRUG

HR20031 FDC

Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fed state .

DRUG

HR20031 FDC

Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fast state.

DRUG

HR20031 FDC

Subjects will receive treatment S HR20031 FDC 5/50/750 mg\*2 in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state.

DRUG

HR20031 FDC

Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fast state.

Trial Locations (1)

210008

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY